MiNK Therapeutics combines its unique, proprietary library of T-cell antigens with ImmunoScape’s cutting-edge platform for rapid discovery of novel T-cell receptors Therapeutic development to focus on novel cell therapies as well as bispecific immune cell engagers against solid tumors SAN DIEGO and NEW YORK and SINGAPORE, Dec.

MiNK Therapeutics将其独特的专有T细胞抗原库与ImmunoScape的前沿平台相结合，用于快速发现新型T细胞受体治疗开发，以专注于新型细胞疗法以及针对实体瘤的双特异性免疫细胞参与者圣地亚哥和纽约以及新加坡，12月。

20, 2023 (GLOBE NEWSWIRE) -- ImmunoScape, a biotechnology company focused on the discovery and development of next-generation T cell receptor (TCR)-based therapeutics, and MiNK Therapeutics, Inc (Nasdaq: INKT), a clinical stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell targeting therapies, today announced a collaboration agreement to discover and develop next-generation TCR therapies against novel targets in solid tumors.

2023年2月20日（环球新闻网）--ImmunoScape是一家专注于发现和开发基于下一代T细胞受体（TCR）的疗法的生物技术公司，而MiNK therapeutics，Inc（纳斯达克股票代码：INKT）是一家临床阶段的生物制药公司，专门从事异基因现成药物的发现，开发和商业化，不变自然杀伤T（iNKT）细胞靶向疗法今天宣布了一项合作协议，以发现和开发针对实体瘤新靶点的下一代TCR疗法。

The combined efforts of both companies aim to accelerate the development of TCR-based therapies against novel targets in T cells, iNKT cells, and other modalities, potentially offering new therapeutic approaches for diverse cancer indications. ImmunoScape’s unique Deep Immunomics platform enables high-throughput and sensitive screening of T cells against relevant tumor targets for the rapid discovery of rare, therapeutically-relevant TCRs.

两家公司的共同努力旨在加速针对T细胞，iNKT细胞和其他方式中的新靶标的基于TCR的疗法的开发，可能为各种癌症适应症提供新的治疗方法。ImmunoScape独特的深度免疫组学平台能够针对相关肿瘤靶标对T细胞进行高通量和灵敏的筛选，以快速发现罕见的治疗相关TCR。

MiNK Therapeutics has a proprietary library of phospho-peptide neoantigens derived from a wide range of solid tumors and hematologic malignancies. In this collaborative effort, ImmunoScape will leverage its capabilities in multiplex antigen screening and in-depth T cell profiling to identify relevant TCRs targeting the library of phospho-peptide antigens.

MiNK Therapeutics拥有一个专有的磷酸肽新抗原库，这些新抗原来源于多种实体瘤和血液系统恶性肿瘤。在这项合作努力中，ImmunoScape将利用其在多重抗原筛选和深入T细胞分析中的能力，以鉴定靶向磷酸肽抗原文库的相关TCR。

MiNK Therapeutics will further characterize these tumor-specific TCRs, leveraging its proprietary capabilities to analyze a.

水貂治疗将进一步表征这些肿瘤特异性TCR，利用其专有功能分析a。